TICKERNERD
Menu
DAREDAREHealthcare · Biotechnology

DARE Stock Forecast: Daré Bioscience, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$0.78
+4.85% on the day

The 3 Wall Street analysts covering Daré Bioscience, Inc. hold a median 12-month price target of $8 — +920.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$14.7M
Ticker Nerd rank
27 / 100
Median analyst target
$8.00
Analysts covering
3
Revenue$188K
Operating income−$3.0M
Net income−$3.0M
Free cash flow−$6.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.1%
1M
+2.1%
YTD
−59.4%
1Y
−62.3%
From 52W high
−76.0%
From 52W low
+11.2%
$0.71
$3.27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DARE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Daré Bioscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Revisions
87
Issuance
50
Quality
30
Value
29
Volatility
23
Accruals
19
Momentum
10
Growth
8

Size (90): Smaller than most of the companies we track.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DARE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DARE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26DAREHigh $12.00Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $5.00Median $8.00High $12.00

The green dot is the last close — the median target sits +920.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Dec 2025HC Wainwright & Co.ReiteratesBuy$12
4 Sept 2025Maxim GroupUpgradeBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024Jones TradingMaintainsBuy—
14 Aug 2024Maxim GroupDowngradeHold—
15 May 2024Brookline CapitalUpgradeBuy—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
1 May 2024HC Wainwright & Co.ReiteratesBuy—
17 Apr 2024Brookline CapitalDowngradeHold—
1 Apr 2024HC Wainwright & Co.ReiteratesBuy—
10 Nov 2023HC Wainwright & Co.MaintainsBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
13 July 2023HC Wainwright & Co.ReiteratesBuy—
6 June 2023HC Wainwright & Co.ReiteratesBuy—
22 May 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.ReiteratesBuy—
31 Mar 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DARE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DARE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Daré Bioscience, Inc. returned −62.3% against +16.3% for the S&P 500, dividends included.

DARE vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Oct 25Jan 26Apr 26Jul 26DARES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DARE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Daré Bioscience, Inc. (DARE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
11.4×

Cheaper than 13% of US stocks

Price / book
−21.0×

Cheaper than 98% of US stocks

EV / EBITDA
−0.6×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
23.0%

Higher than 72% of US stocks

Earnings growth (YoY)
−985.8%

Higher than 1% of US stocks

Gross margin
−70.6%

Higher than 2% of US stocks

Operating margin
−1582.5%

Higher than 5% of US stocks

Net margin
71.3%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−471.4%

Higher than 3% of US stocks

Return on assets
−39.3%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Daré Bioscience, Inc. (DARE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Daré Bioscience, Inc. has a market value of $14.7M and an enterprise value of $5.6M.

  • Revenue in the twelve months to 30 June 2026: $1.4M. The latest quarter grew 23.0% year on year.

  • Net income over the same four quarters: −$11.0M, a −804.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$11.8M.

  • Shares outstanding: 15.2M.

  • Trailing P/E: 0.1×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Daré Bioscience, Inc. employs 21 people — $65K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

DARE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DAREDaré Bioscience, Inc.$14.7M
27
PASGPassage Bio, Inc.$15.3M
43
LSTALisata Therapeutics, Inc.$15.3M
56
MBRXMoleculin Biotech, Inc.$15.1M
25
CNSYCerenome, Inc.$15.4M
17
TPSTTempest Therapeutics, Inc.$15.5M
37
ICUSeastar Medical Holding Corp.$15.6M
21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Daré Bioscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DARE news & analysis

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

GlobeNewsWire · 14 Sept 2026positive

Daré Bioscience announced the peer-reviewed publication of Phase 1 data from its Sildenafil Cream study in men, which appeared in Sexual Medicine. The data demonstrated substantially lower systemic exposure with the topical Sildenafil Cream, 3.6% compared to oral sildenafil, strengthening the scientific foundation for the company's proprietary product.

Why it matters — Peer-reviewed publication of Phase 1 data supports the scientific credibility and differentiation of Daré's topical Sildenafil Cream, a key pipeline asset for the company.

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

GlobeNewsWire · 11 Sept 2026neutral

Daré Bioscience announced that its presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available on-demand via video webcast. The company's presentation was provided for viewing by investors and interested parties.

Why it matters — A DARE watcher would care because the on-demand availability offers an opportunity to access the company's latest corporate update and investment conference presentation.

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

GlobeNewsWire · 31 Aug 2026positive

Daré Bioscience announced a new NIH funding award of approximately $908,000 to support year-long preclinical development of DARE-PTB2 for the prevention of preterm birth, with potential for an additional future-year grant of approximately $1.3 million.

Why it matters — A DARE watcher would care because the NIH award provides non-dilutive funding that advances the preclinical development of DARE-PTB2, one of the company's pipeline candidates.

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript

Seeking Alpha · 26 Aug 2026neutral

Daré Bioscience, Inc. discussed its women's health portfolio and commercial launch plans during a virtual bus tour transcript published by Seeking Alpha. The company provided an overview of its product pipeline and commercialization strategy.

Why it matters — A DARE watcher would care because the discussion offers insight into the company's portfolio and commercial launch progress.

FAQ

Frequently asked questions about DARE stock

What is the DARE stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Daré Bioscience, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DARE stock a buy right now?

Of the 3 analysts covering Daré Bioscience, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Daré Bioscience, Inc. 27 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DARE?

As at 19 Sept 2026, Daré Bioscience, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will DARE stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +920.0% from the last close, and Ticker Nerd's factor model ranks Daré Bioscience, Inc. 27 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DARE stock forecast for 2030?

No analyst covering Daré Bioscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DARE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $12 over the next 12 months.

How has DARE stock performed over the past year?

Daré Bioscience, Inc. returned -62.3% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Daré Bioscience, Inc. do?

Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on women’s health.

What is the latest news on DARE?

The most recent item we track (GlobeNewsWire, 14 Sept 2026): "Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil". Daré Bioscience announced the peer-reviewed publication of Phase 1 data from its Sildenafil Cream study in men, which appeared in Sexual Medicine. The data demonstrated substantially lower systemic exposure with the topical Sildenafil Cream, 3.6% compared to oral sildenafil, strengthening the scientific foundation for the company's proprietary product.

Company

About Daré Bioscience, Inc.

Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on women’s health. Daré Bioscience develops and commercializes therapies in contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health, with an emphasis on improving treatment options and convenience for women. Its portfolio includes approved and investigational products designed to address unmet needs in reproductive and intimate health, such as non-hormonal contraception, vaginal health treatments, and hormone-related therapies. The company operates as a product-driven biotech business, advancing candidates through clinical development and regulatory pathways in the United States. Headquartered in San Diego, California, Daré Bioscience plays a specialized role in the healthcare market by concentrating on differentiated solutions for areas that are often underrepresented in women’s medicine.

CEO Ms. Sabrina Martucci Johnson · 21 employees · United States · https://darebioscience.com